Hansa Biopharma AB (HNSBF)
3.65
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Hansa Biopharma Gross Profit Margin (Quarterly): 76.62% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 76.62% |
| June 30, 2024 | -18.04% |
| March 31, 2024 | 67.56% |
| December 31, 2023 | 64.04% |
| September 30, 2023 | 27.07% |
| June 30, 2023 | 48.94% |
| March 31, 2023 | 60.13% |
| December 31, 2022 | 85.26% |
| September 30, 2022 | 73.71% |
| June 30, 2022 | 80.77% |
| March 31, 2022 | 62.90% |
| December 31, 2021 | 76.47% |
| September 30, 2021 | -56.39% |
| June 30, 2021 | 48.56% |
| March 31, 2021 | 80.73% |
| December 31, 2020 | 95.48% |
| September 30, 2020 | 62.60% |
| June 30, 2020 | 81.38% |
| March 31, 2020 | 52.20% |
| December 31, 2019 | 86.70% |
| September 30, 2019 | 68.10% |
| June 30, 2019 | 83.62% |
| Date | Value |
|---|---|
| March 31, 2019 | 56.27% |
| December 31, 2018 | 44.81% |
| September 30, 2018 | 89.67% |
| June 30, 2018 | 94.33% |
| March 31, 2018 | 91.50% |
| December 31, 2017 | 94.77% |
| September 30, 2017 | 92.04% |
| June 30, 2017 | 92.35% |
| March 31, 2017 | 94.23% |
| December 31, 2016 | 90.06% |
| September 30, 2016 | 93.94% |
| June 30, 2016 | 90.04% |
| March 31, 2016 | 90.80% |
| December 31, 2015 | 62.82% |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | 90.38% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-56.39%
Minimum
Sep 2021
95.48%
Maximum
Dec 2020
57.83%
Average
65.80%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Abliva AB | -- |
| Oncopeptides AB | -- |
| BioInvent International AB | -- |
| BioArctic AB | 90.35% |
| Camurus AB | 93.01% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -65.34% |
| Return on Invested Capital | -95.02% |
| Profit Margin (Quarterly) | -213.3% |
| Operating Margin (Quarterly) | -240.3% |
| Return on Net Operating Assets | -209.6% |